The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.

Charokopou, M; McEwan, P; Lister, S; Callan, L; Bergenheim, K; Tolley, K; Postema, R; Townsend, R; Roudaut, M

The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.

Charokopou, M; McEwan, P; Lister, S; Callan, L; Bergenheim, K; Tolley, K; Postema, R; Townsend, R; Roudaut, M.

Affiliation

Charokopou M; Pharmerit International, Rotterdam, The Netherlands.
McEwan P; Centre for Health Economics, Swansea University, Monmouth, UK.
Lister S; HEOR, Monmouth, UK.
Callan L; Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK.
Bergenheim K; AstraZeneca UK, Luton, UK.
Tolley K; AstraZeneca, Mölndal, Sweden.
Postema R; Tolley Health Economics, Buxton, UK.
Townsend R; Bristol-Myers Squibb, Rueil-Malmaison, France.
Roudaut M; AstraZeneca, Brussels, Belgium.

Diabet Med ; 32(7): 890-8, 2015 Jul.

Article in En | MEDLINE | ID: mdl-25817050

Subject(s)

Benzhydryl Compounds/therapeutic use; Diabetes Mellitus, Type 2/drug therapy; Glucosides/therapeutic use; Hyperglycemia/prevention & control; Hypoglycemia/prevention & control; Hypoglycemic Agents/therapeutic use; Metformin/therapeutic use; Sodium-Glucose Transport Proteins/antagonists & inhibitors; Benzhydryl Compounds/adverse effects; Benzhydryl Compounds/economics; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications/economics; Diabetes Complications/epidemiology; Diabetes Complications/prevention & control; Diabetes Complications/therapy; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/economics; Diabetes Mellitus, Type 2/metabolism; Drug Resistance; Drug Therapy, Combination/adverse effects; Drug Therapy, Combination/economics; Female; Glucosides/adverse effects; Glucosides/economics; Health Care Costs; Humans; Hyperglycemia/economics; Hyperglycemia/therapy; Hypoglycemia/chemically induced; Hypoglycemia/economics; Hypoglycemia/therapy; Hypoglycemic Agents/adverse effects; Hypoglycemic Agents/economics; Male; Metformin/adverse effects; Metformin/economics; Middle Aged; Overweight/economics; Overweight/epidemiology; Overweight/prevention & control; Overweight/therapy; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins/metabolism; Sulfonylurea Compounds/adverse effects; Sulfonylurea Compounds/economics; Sulfonylurea Compounds/therapeutic use; United Kingdom/epidemiology; Weight Loss/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzhydryl Compounds / Diabetes Mellitus, Type 2 / Sodium-Glucose Transport Proteins / Glucosides / Hyperglycemia / Hypoglycemia / Hypoglycemic Agents / Metformin Type of study: Clinical_trials / Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Country/Region as subject: Europa Language: En Journal: Diabet Med Journal subject: ENDOCRINOLOGIA Year: 2015 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google